Study to Assess the Safety and Effectiveness of NMRA-335140-501

Running, not enrolling · Phase 3

Conditions studied: Major Depressive Disorder

In brief

This is a 52-week open-label extension (OLE) study that will evaluate the safety, tolerability, and effectiveness of NMRA-335140 in participants with major depressive disorder (MDD). Participants who completed a parent study investigating the efficacy and safety of NMRA-335140 as a treatment for MDD (ie, NMRA-335140-301, NMRA-335140-302, or NMRA-335140-303), and complete the 6 weeks double-blind treatment, provide informed consent, and meet eligibility criteria, may enter this extension study.

Key facts

Study ID
NCT06029439
Run by
Neumora Therapeutics, Inc.
People needed
1000
Starts
2023-11-10
Expected to finish
2027-06-01
Last updated by the study team
2026-06-09

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.